+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Future of Drug Addiction R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4749235
  • Report
  • February 2019
  • Region: Global
  • 150 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • BioCorRx Inc
  • Curemark LLC
  • F. Hoffmann-La Roche Ltd
  • Kdac Therapeutics Inc
  • MElkin Pharmaceuticals
  • MORE
The global demand for Drug Addiction treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Drug Addiction pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Drug Addiction pipeline companies from advancing their products into Phase 3 or Phase 4.

Drug Addiction Report Description

The 2019 pipeline study on Drug Addiction pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Drug Addiction pipeline compounds.

The Drug Addiction pipeline guide presents information on all active drugs currently being developed for Drug Addiction. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Drug Addiction pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Drug Addiction drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Drug Addiction product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Drug Addiction pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Drug Addiction pipeline report includes
  • An overview of Drug Addiction disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of Drug Addiction pipeline
  • Company wise list of Drug Addiction pipeline
  • Mechanism of Action wise Drug Addiction pipeline
For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials/Results
  • Company Overview and Recent Developments
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Drug Addiction pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Drug Addiction pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into companies participating in Drug Addiction pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • BioCorRx Inc
  • Curemark LLC
  • F. Hoffmann-La Roche Ltd
  • Kdac Therapeutics Inc
  • MElkin Pharmaceuticals
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Drug Addiction Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. Executive Summary
3.1 Drug Addiction Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Drug Addiction pipeline, H1- 2019
3.5 Mechanism of Action wise Drug Addiction Pipeline Candidates

4 Addex Therapeutics Ltd Drug Addiction Pipeline Details
4.1 Addex Therapeutics Ltd Business Profile
4.2 Addex Therapeutics Ltd Drug Addiction Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 Aelis Farma SAS Drug Addiction Pipeline Details
5.1 Aelis Farma SAS Business Profile
5.2 Aelis Farma SAS Drug Addiction Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 Amygdala Neurosciences Inc Drug Addiction Pipeline Details
6.1 Amygdala Neurosciences Inc Business Profile
6.2 Amygdala Neurosciences Inc Drug Addiction Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 Aphios Corp Drug Addiction Pipeline Details
7.1 Aphios Corp Business Profile
7.2 Aphios Corp Drug Addiction Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 Astraea Therapeutics LLC Drug Addiction Pipeline Details
8.1 Astraea Therapeutics LLC Business Profile
8.2 Astraea Therapeutics LLC Drug Addiction Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 BioCorRx Inc Drug Addiction Pipeline Details
9.1 BioCorRx Inc Business Profile
9.2 BioCorRx Inc Drug Addiction Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 Camino Pharma LLC Drug Addiction Pipeline Details
10.1 Camino Pharma LLC Business Profile
10.2 Camino Pharma LLC Drug Addiction Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 Charleston Laboratories Inc Drug Addiction Pipeline Details
11.1 Charleston Laboratories Inc Business Profile
11.2 Charleston Laboratories Inc Drug Addiction Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 Chiesi Farmaceutici SpA Drug Addiction Pipeline Details
12.1 Chiesi Farmaceutici SpA Business Profile
12.2 Chiesi Farmaceutici SpA Drug Addiction Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13 Consegna Pharma Inc Drug Addiction Pipeline Details
13.1 Consegna Pharma Inc Business Profile
13.2 Consegna Pharma Inc Drug Addiction Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14 Curemark LLC Drug Addiction Pipeline Details
14.1 Curemark LLC Business Profile
14.2 Curemark LLC Drug Addiction Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15 Daya Drug Discoveries Inc Drug Addiction Pipeline Details
15.1 Daya Drug Discoveries Inc Business Profile
15.2 Daya Drug Discoveries Inc Drug Addiction Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16 Egalet Corp Drug Addiction Pipeline Details
16.1 Egalet Corp Business Profile
16.2 Egalet Corp Drug Addiction Drug Details
16.3 Drug Snapshot
16.3.1 Originator
16.3.2 Collaborator/Co-Developer
16.3.3 Route of Administration
16.3.4 Orphan Drug/Fast Track/Special Designation
16.3.5 Geography
16.3.6 Type of Molecular Entity
16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments

17 Embera NeuroTherapeutics Inc Drug Addiction Pipeline Details
17.1 Embera NeuroTherapeutics Inc Business Profile
17.2 Embera NeuroTherapeutics Inc Drug Addiction Drug Details
17.3 Drug Snapshot
17.3.1 Originator
17.3.2 Collaborator/Co-Developer
17.3.3 Route of Administration
17.3.4 Orphan Drug/Fast Track/Special Designation
17.3.5 Geography
17.3.6 Type of Molecular Entity
17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments

18 EncepHeal Therapeutics Inc Drug Addiction Pipeline Details
18.1 EncepHeal Therapeutics Inc Business Profile
18.2 EncepHeal Therapeutics Inc Drug Addiction Drug Details
18.3 Drug Snapshot
18.3.1 Originator
18.3.2 Collaborator/Co-Developer
18.3.3 Route of Administration
18.3.4 Orphan Drug/Fast Track/Special Designation
18.3.5 Geography
18.3.6 Type of Molecular Entity
18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments

19 Eolas Therapeutics Inc Drug Addiction Pipeline Details
19.1 Eolas Therapeutics Inc Business Profile
19.2 Eolas Therapeutics Inc Drug Addiction Drug Details
19.3 Drug Snapshot
19.3.1 Originator
19.3.2 Collaborator/Co-Developer
19.3.3 Route of Administration
19.3.4 Orphan Drug/Fast Track/Special Designation
19.3.5 Geography
19.3.6 Type of Molecular Entity
19.3.7 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments

20 F. Hoffmann-La Roche Ltd Drug Addiction Pipeline Details
20.1 F. Hoffmann-La Roche Ltd Business Profile
20.2 F. Hoffmann-La Roche Ltd Drug Addiction Drug Details
20.3 Drug Snapshot
20.3.1 Originator
20.3.2 Collaborator/Co-Developer
20.3.3 Route of Administration
20.3.4 Orphan Drug/Fast Track/Special Designation
20.3.5 Geography
20.3.6 Type of Molecular Entity
20.3.7 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments

21 Foresee Pharmaceuticals Co Ltd Drug Addiction Pipeline Details
21.1 Foresee Pharmaceuticals Co Ltd Business Profile
21.2 Foresee Pharmaceuticals Co Ltd Drug Addiction Drug Details
21.3 Drug Snapshot
21.3.1 Originator
21.3.2 Collaborator/Co-Developer
21.3.3 Route of Administration
21.3.4 Orphan Drug/Fast Track/Special Designation
21.3.5 Geography
21.3.6 Type of Molecular Entity
21.3.7 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments

22 Heptares Therapeutics Ltd Drug Addiction Pipeline Details
22.1 Heptares Therapeutics Ltd Business Profile
22.2 Heptares Therapeutics Ltd Drug Addiction Drug Details
22.3 Drug Snapshot
22.3.1 Originator
22.3.2 Collaborator/Co-Developer
22.3.3 Route of Administration
22.3.4 Orphan Drug/Fast Track/Special Designation
22.3.5 Geography
22.3.6 Type of Molecular Entity
22.3.7 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments

23 IMV Inc Drug Addiction Pipeline Details
23.1 IMV Inc Business Profile
23.2 IMV Inc Drug Addiction Drug Details
23.3 Drug Snapshot
23.3.1 Originator
23.3.2 Collaborator/Co-Developer
23.3.3 Route of Administration
23.3.4 Orphan Drug/Fast Track/Special Designation
23.3.5 Geography
23.3.6 Type of Molecular Entity
23.3.7 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments

24 InterveXion Therapeutics LLC Drug Addiction Pipeline Details
24.1 InterveXion Therapeutics LLC Business Profile
24.2 InterveXion Therapeutics LLC Drug Addiction Drug Details
24.3 Drug Snapshot
24.3.1 Originator
24.3.2 Collaborator/Co-Developer
24.3.3 Route of Administration
24.3.4 Orphan Drug/Fast Track/Special Designation
24.3.5 Geography
24.3.6 Type of Molecular Entity
24.3.7 Current Status
24.4 Drug Overview
24.5 Drug Mechanism of Action
24.6 Clinical/Pre-clinical Trial Details
24.7 Latest Drug Developments

25 InterveXion Therapeutics LLC Drug Addiction Pipeline Details
25.1 InterveXion Therapeutics LLC Business Profile
25.2 InterveXion Therapeutics LLC Drug Addiction Drug Details
25.3 Drug Snapshot
25.3.1 Originator
25.3.2 Collaborator/Co-Developer
25.3.3 Route of Administration
25.3.4 Orphan Drug/Fast Track/Special Designation
25.3.5 Geography
25.3.6 Type of Molecular Entity
25.3.7 Current Status
25.4 Drug Overview
25.5 Drug Mechanism of Action
25.6 Clinical/Pre-clinical Trial Details
25.7 Latest Drug Developments

26 Intra-Cellular Therapies Inc Drug Addiction Pipeline Details
26.1 Intra-Cellular Therapies Inc Business Profile
26.2 Intra-Cellular Therapies Inc Drug Addiction Drug Details
26.3 Drug Snapshot
26.3.1 Originator
26.3.2 Collaborator/Co-Developer
26.3.3 Route of Administration
26.3.4 Orphan Drug/Fast Track/Special Designation
26.3.5 Geography
26.3.6 Type of Molecular Entity
26.3.7 Current Status
26.4 Drug Overview
26.5 Drug Mechanism of Action
26.6 Clinical/Pre-clinical Trial Details
26.7 Latest Drug Developments

27 Johnson & Johnson Drug Addiction Pipeline Details
27.1 Johnson & Johnson Business Profile
27.2 Johnson & Johnson Drug Addiction Drug Details
27.3 Drug Snapshot
27.3.1 Originator
27.3.2 Collaborator/Co-Developer
27.3.3 Route of Administration
27.3.4 Orphan Drug/Fast Track/Special Designation
27.3.5 Geography
27.3.6 Type of Molecular Entity
27.3.7 Current Status
27.4 Drug Overview
27.5 Drug Mechanism of Action
27.6 Clinical/Pre-clinical Trial Details
27.7 Latest Drug Developments

28 Kdac Therapeutics Inc Drug Addiction Pipeline Details
28.1 Kdac Therapeutics Inc Business Profile
28.2 Kdac Therapeutics Inc Drug Addiction Drug Details
28.3 Drug Snapshot
28.3.1 Originator
28.3.2 Collaborator/Co-Developer
28.3.3 Route of Administration
28.3.4 Orphan Drug/Fast Track/Special Designation
28.3.5 Geography
28.3.6 Type of Molecular Entity
28.3.7 Current Status
28.4 Drug Overview
28.5 Drug Mechanism of Action
28.6 Clinical/Pre-clinical Trial Details
28.7 Latest Drug Developments

29 Kyorin Pharmaceutical Co Ltd Drug Addiction Pipeline Details
29.1 Kyorin Pharmaceutical Co Ltd Business Profile
29.2 Kyorin Pharmaceutical Co Ltd Drug Addiction Drug Details
29.3 Drug Snapshot
29.3.1 Originator
29.3.2 Collaborator/Co-Developer
29.3.3 Route of Administration
29.3.4 Orphan Drug/Fast Track/Special Designation
29.3.5 Geography
29.3.6 Type of Molecular Entity
29.3.7 Current Status
29.4 Drug Overview
29.5 Drug Mechanism of Action
29.6 Clinical/Pre-clinical Trial Details
29.7 Latest Drug Developments

30 Kyowa Hakko Kirin Co Ltd Drug Addiction Pipeline Details
30.1 Kyowa Hakko Kirin Co Ltd Business Profile
30.2 Kyowa Hakko Kirin Co Ltd Drug Addiction Drug Details
30.3 Drug Snapshot
30.3.1 Originator
30.3.2 Collaborator/Co-Developer
30.3.3 Route of Administration
30.3.4 Orphan Drug/Fast Track/Special Designation
30.3.5 Geography
30.3.6 Type of Molecular Entity
30.3.7 Current Status
30.4 Drug Overview
30.5 Drug Mechanism of Action
30.6 Clinical/Pre-clinical Trial Details
30.7 Latest Drug Developments

31 MAKScientific LLC Drug Addiction Pipeline Details
31.1 MAKScientific LLC Business Profile
31.2 MAKScientific LLC Drug Addiction Drug Details
31.3 Drug Snapshot
31.3.1 Originator
31.3.2 Collaborator/Co-Developer
31.3.3 Route of Administration
31.3.4 Orphan Drug/Fast Track/Special Designation
31.3.5 Geography
31.3.6 Type of Molecular Entity
31.3.7 Current Status
31.4 Drug Overview
31.5 Drug Mechanism of Action
31.6 Clinical/Pre-clinical Trial Details
31.7 Latest Drug Developments

32 Mayo Clinic Drug Addiction Pipeline Details
32.1 Mayo Clinic Business Profile
32.2 Mayo Clinic Drug Addiction Drug Details
32.3 Drug Snapshot
32.3.1 Originator
32.3.2 Collaborator/Co-Developer
32.3.3 Route of Administration
32.3.4 Orphan Drug/Fast Track/Special Designation
32.3.5 Geography
32.3.6 Type of Molecular Entity
32.3.7 Current Status
32.4 Drug Overview
32.5 Drug Mechanism of Action
32.6 Clinical/Pre-clinical Trial Details
32.7 Latest Drug Developments

33 MElkin Pharmaceuticals Drug Addiction Pipeline Details
33.1 MElkin Pharmaceuticals Business Profile
33.2 MElkin Pharmaceuticals Drug Addiction Drug Details
33.3 Drug Snapshot
33.3.1 Originator
33.3.2 Collaborator/Co-Developer
33.3.3 Route of Administration
33.3.4 Orphan Drug/Fast Track/Special Designation
33.3.5 Geography
33.3.6 Type of Molecular Entity
33.3.7 Current Status
33.4 Drug Overview
33.5 Drug Mechanism of Action
33.6 Clinical/Pre-clinical Trial Details
33.7 Latest Drug Developments

34 NLS Pharma Group Drug Addiction Pipeline Details
34.1 NLS Pharma Group Business Profile
34.2 NLS Pharma Group Drug Addiction Drug Details
34.3 Drug Snapshot
34.3.1 Originator
34.3.2 Collaborator/Co-Developer
34.3.3 Route of Administration
34.3.4 Orphan Drug/Fast Track/Special Designation
34.3.5 Geography
34.3.6 Type of Molecular Entity
34.3.7 Current Status
34.4 Drug Overview
34.5 Drug Mechanism of Action
34.6 Clinical/Pre-clinical Trial Details
34.7 Latest Drug Developments

35 Omeros Corp Drug Addiction Pipeline Details
35.1 Omeros Corp Business Profile
35.2 Omeros Corp Drug Addiction Drug Details
35.3 Drug Snapshot
35.3.1 Originator
35.3.2 Collaborator/Co-Developer
35.3.3 Route of Administration
35.3.4 Orphan Drug/Fast Track/Special Designation
35.3.5 Geography
35.3.6 Type of Molecular Entity
35.3.7 Current Status
35.4 Drug Overview
35.5 Drug Mechanism of Action
35.6 Clinical/Pre-clinical Trial Details
35.7 Latest Drug Developments

36 Orexigen Therapeutics Inc Drug Addiction Pipeline Details
36.1 Orexigen Therapeutics Inc Business Profile
36.2 Orexigen Therapeutics Inc Drug Addiction Drug Details
36.3 Drug Snapshot
36.3.1 Originator
36.3.2 Collaborator/Co-Developer
36.3.3 Route of Administration
36.3.4 Orphan Drug/Fast Track/Special Designation
36.3.5 Geography
36.3.6 Type of Molecular Entity
36.3.7 Current Status
36.4 Drug Overview
36.5 Drug Mechanism of Action
36.6 Clinical/Pre-clinical Trial Details
36.7 Latest Drug Developments

37 Phoenix PharmaLabs Drug Addiction Pipeline Details
37.1 Phoenix PharmaLabs Business Profile
37.2 Phoenix PharmaLabs Drug Addiction Drug Details
37.3 Drug Snapshot
37.3.1 Originator
37.3.2 Collaborator/Co-Developer
37.3.3 Route of Administration
37.3.4 Orphan Drug/Fast Track/Special Designation
37.3.5 Geography
37.3.6 Type of Molecular Entity
37.3.7 Current Status
37.4 Drug Overview
37.5 Drug Mechanism of Action
37.6 Clinical/Pre-clinical Trial Details
37.7 Latest Drug Developments

38 Saniona AB Drug Addiction Pipeline Details
38.1 Saniona AB Business Profile
38.2 Saniona AB Drug Addiction Drug Details
38.3 Drug Snapshot
38.3.1 Originator
38.3.2 Collaborator/Co-Developer
38.3.3 Route of Administration
38.3.4 Orphan Drug/Fast Track/Special Designation
38.3.5 Geography
38.3.6 Type of Molecular Entity
38.3.7 Current Status
38.4 Drug Overview
38.5 Drug Mechanism of Action
38.6 Clinical/Pre-clinical Trial Details
38.7 Latest Drug Developments

39 Savant HWP Inc Drug Addiction Pipeline Details
39.1 Savant HWP Inc Business Profile
39.2 Savant HWP Inc Drug Addiction Drug Details
39.3 Drug Snapshot
39.3.1 Originator
39.3.2 Collaborator/Co-Developer
39.3.3 Route of Administration
39.3.4 Orphan Drug/Fast Track/Special Designation
39.3.5 Geography
39.3.6 Type of Molecular Entity
39.3.7 Current Status
39.4 Drug Overview
39.5 Drug Mechanism of Action
39.6 Clinical/Pre-clinical Trial Details
39.7 Latest Drug Developments

40 Seropeutics LLC Drug Addiction Pipeline Details
40.1 Seropeutics LLC Business Profile
40.2 Seropeutics LLC Drug Addiction Drug Details
40.3 Drug Snapshot
40.3.1 Originator
40.3.2 Collaborator/Co-Developer
40.3.3 Route of Administration
40.3.4 Orphan Drug/Fast Track/Special Designation
40.3.5 Geography
40.3.6 Type of Molecular Entity
40.3.7 Current Status
40.4 Drug Overview
40.5 Drug Mechanism of Action
40.6 Clinical/Pre-clinical Trial Details
40.7 Latest Drug Developments

41 SpringWorks Therapeutics LLC Drug Addiction Pipeline Details
41.1 SpringWorks Therapeutics LLC Business Profile
41.2 SpringWorks Therapeutics LLC Drug Addiction Drug Details
41.3 Drug Snapshot
41.3.1 Originator
41.3.2 Collaborator/Co-Developer
41.3.3 Route of Administration
41.3.4 Orphan Drug/Fast Track/Special Designation
41.3.5 Geography
41.3.6 Type of Molecular Entity
41.3.7 Current Status
41.4 Drug Overview
41.5 Drug Mechanism of Action
41.6 Clinical/Pre-clinical Trial Details
41.7 Latest Drug Developments

42 Zynerba Pharmaceuticals Inc Drug Addiction Pipeline Details
42.1 Zynerba Pharmaceuticals Inc Business Profile
42.2 Zynerba Pharmaceuticals Inc Drug Addiction Drug Details
42.3 Drug Snapshot
42.3.1 Originator
42.3.2 Collaborator/Co-Developer
42.3.3 Route of Administration
42.3.4 Orphan Drug/Fast Track/Special Designation
42.3.5 Geography
42.3.6 Type of Molecular Entity
42.3.7 Current Status
42.4 Drug Overview
42.5 Drug Mechanism of Action
42.6 Clinical/Pre-clinical Trial Details
42.7 Latest Drug Developments

43. Latest Drug Addiction Drug Pipeline Developments, 2019

44. Appendix
44.1 About Us
44.2 Sources and Methodology
44.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3
  • Addex Therapeutics Ltd
  • Aelis Farma SAS
  • Amygdala Neurosciences Inc
  • Aphios Corp
  • Astraea Therapeutics LLC
  • BioCorRx Inc
  • Camino Pharma LLC
  • Charleston Laboratories Inc
  • Chiesi Farmaceutici SpA
  • Consegna Pharma Inc
  • Curemark LLC
  • Daya Drug Discoveries Inc
  • Egalet Corp
  • Embera NeuroTherapeutics Inc
  • EncepHeal Therapeutics Inc
  • Eolas Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Foresee Pharmaceuticals Co Ltd
  • Heptares Therapeutics Ltd
  • IMV Inc
  • InterveXion Therapeutics LLC
  • InterveXion Therapeutics LLC
  • Intra-Cellular Therapies Inc
  • Johnson & Johnson
  • Kdac Therapeutics Inc
  • Kyorin Pharmaceutical Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • MAKScientific LLC
  • Mayo Clinic
  • MElkin Pharmaceuticals
  • NLS Pharma Group
  • Omeros Corp
  • Orexigen Therapeutics Inc
  • Phoenix PharmaLabs
  • Saniona AB
  • Savant HWP Inc
  • Seropeutics LLC
  • SpringWorks Therapeutics LLC
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll